Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cingulate Inc. - Warrants (NQ: CINGW )

0.0416 -0.0082 (-16.47%)
Streaming Delayed Price Updated: 3:55 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,700
Open 0.0498
Bid (Size) 0.0416 (30)
Ask (Size) 0.0498 (246)
Prev. Close 0.0498
Today's Range 0.0411 - 0.0498
52wk Range 0.0070 - 0.1800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
Data Accepted as Finalist for First Annual Poster Awards 
From Cingulate Inc.
Via GlobeNewswire
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire

Performance

YTD
+39.13%
+39.13%
1 Month
-35.30%
-35.30%
3 Month
+362.22%
+362.22%
6 Month
+92.59%
+92.59%
1 Year
-40.83%
-40.83%

More News

Read More
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
From Cingulate Inc.
Via GlobeNewswire
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
Cingulate to Present at 13th Annual LD Micro Invitational
From Cingulate Inc.
Via GlobeNewswire
Cingulate, Indegene to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
From Cingulate Inc.
Via GlobeNewswire
Cingulate to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.